Our Featured Research Page lists cancer prevention, treatment and quality of life studies enrolling people with or at high risk for hereditary cancers. Sign up for our community newsletter to stay up-to-date on the latest hereditary cancer research.
Featured Studies Results
Study Type: Treatment | Keyword: BARD1
NePtune: Using PARP Inhibitors Before Surgery in Localized Prostate Cancer
Clinicaltrials.gov identifier:
NCT05498272
Treatment
Treatment study for people with intermediate- or high-risk prostate cancer with certain tumor mutations
Treating Metastatic Solid Tumors with an Inherited or Acquired Gene Mutation Using the PARP Inhibitor Talazoparib
Clinicaltrials.gov identifier:
NCT04550494
Treatment
Treatment study for people with advanced solid tumors
Treating Metastatic Prostate Cancer with Chemotherapy or PARP Inhibitor in People with Mutations (COBRA)
Clinicaltrials.gov identifier:
NCT04038502
Treatment
Treatment study for mCRPC with an inherited or tumor mutation in BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D or RAD54L
Pembrolizumab and Olaparib for Metastatic Pancreatic Cancer with Homologous Recombination Deficiency or Exceptional Response to Platinum Chemotherapy
Clinicaltrials.gov identifier:
NCT04666740
Treatment
Treatment study for people diagnosed with metastatic pancreatic cancer with Homologous Recombination Deficiency, or whose disease has responded well to first-line or second-line platinum therapy
If you would like a more in-depth search, visit our In-Depth Search Tool that searches for studies in FORCE’s database and in clinicaltrials.gov
Sponsored By:
